Nanobiotix is developing a way for the company’s locally injected radioenhancer for solid tumors to treat metastasized cancers, in combination with checkpoint inhibitors, and also deliver results distally.

Boston Scientific announced a definitive agreement to acquire Augmenix Inc., a privately held company that has developed and commercialized the SpaceOAR System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.